TAILIEUCHUNG - Molecular Basis of Pulmonary Disease Insights from Rare Lung Disorders

Dr. Sharon Rounds, the editor for this series who invited us to write a book on rare lung diseases, developed the idea after attending the 2004 Lymphangioleiomyomatosis (LAM) Foundation annual research meeting. She was a keynote speaker at that event (during her tenure as the president of the American Thoracic Society) and was witness to the power of patient advocacy and the mission-based scientific effort that had brought this rare disease of women from obscurity to clinical trials with targeted molecular therapies in under a decade. The progress in pulmonary alveolar proteinosis (PAP), pulmonary alveolar microlithiasis (PAM), inherited disorders of surfactant metabolism, and pulmonary arterial hypertension, to name. | Molecular Basis of Pulmonary Disease Insights from Rare Lung Disorders Edited by Francis X. McCormack MD Ralph J. Panos MD Bruce c. I Humana Press Molecular Basis of Pulmonary Disease Respiratory Medicine Sharon R. Rounds MD Series Editor Molecular Basis of Pulmonary Disease edited by Francis X. McCormack Ralph J. Panos and Bruce C. Trapnell 2010 Pulmonary Problems in Pregnancy edited by Ghada Bourjeily and Karen Rosene-Montella .

• Y học thường thức
• Arterial Hypertension
• Familial Pulmonary
• Alveolar Proteinosis
• Haemorrhagic Telangiectasia
• Lung Disease
• Alveolar Microlithiasis
• New ESC ESH Guidelines 2018
• Management of arterial hypertension
• Screening for HTN
• Screening and diagnosis of hypertension
• BMC Pulmonary Medicine
• Pulmonary arterial hypertension
• Vascular disease
• Idiopathic pulmonary arterial hypertension
• In situ thrombosis
• Systemic artery to pulmonary artery fistulas
• Nonreversible arterial pulmonary hypertension
• Above mentioned risk factors
• Cysteine rich 61
• Pulmonary arterial smooth muscle cells
• Specific siRNA
• Quantitative real time polymerase chain
• BMC Pediatrics
• Infantile arterial calcification
• Pulmonary hypertension
• Idiopathic infantile arterial calcification
• Rare autosomal recessive disorder
• Primary pulmonary hypertension
• Phosphodiesterase type 5
• Health expenditure
• Cyclic guanosine monophosphate
• Chronic thromboembolic pulmonary hypertension
• PAH medications
• White blood cell count
• C reactive protein
• Progressive disease
• Idiopathic PAH
• Portopulmonary hypertension
• Portal hypertension
• Cardiac outputs
• World Symposium on Pulmonary Hypertension
• Pulmonary artery wedge pressure
• Pulmonary vascular resistance
• báo cáo khao học
• báo cáo y học
• báo cáo về y học
• công trình y học
• nghiên cứu y học
• The oxygenation and circulation of blood
• Blood pressure
• The difference between PH and PAH
• The structure of the heart
• Your clinic appointments
• Tests for PAH
• Targeted therapy
• When medication is not enough
• Living your life
• Congenital heart disease
• endothelial progenitor cells
• Atrial aeptal defect
• Health related quality of life
• Childhood obesity epidemic
• Public health concern
• Fibrous obstruction
• Pulmonary veins
• Brain natriuretic peptide
• Functional classes II
• Non parenteral therapies
• Including endothelin receptor antagonists
• Pharmacologic intervention
• Parental proxy response
• Regression analyses
• Peak oxygen consumption
• Exercise training
• Exercise capacity
• Quality of life
• Phosphodiesterase type 5 inhibitor
• New treatment option
• Multi drug resistant PAH
• Pulmonary artery
• Computed tomography
• Aneurismal dilation
• Risk assessment score
• Survival rate
• 6 min walk distance
• High sensitive Troponin T
• Cardiopulmonary exercise testing
• Maximal physical exercise
• Czech republic
• National registry
• Right heart failure
• Increased pulmonary vascular resistance